# To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

> **NCT03880357** · PHASE1 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 485 (actual)

## Conditions studied

- Scalp Psoriasis

## Interventions

- **DRUG:** Betamethasone Scalp Suspension 0.064%;0.0005%
- **DRUG:** Taclonex®
- **DRUG:** Placebo topical suspension

## Key facts

- **NCT ID:** NCT03880357
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-22
- **Primary completion:** 2019-03-15
- **Final completion:** 2019-03-15
- **Target enrollment:** 485 (ACTUAL)
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03880357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03880357, "To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03880357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*